HC Wainwright Issues Pessimistic Outlook for KZR Earnings

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Equities researchers at HC Wainwright dropped their Q4 2024 earnings estimates for shares of Kezar Life Sciences in a note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($2.59) per share for the quarter, down from their prior estimate of ($1.70). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.30) per share. HC Wainwright also issued estimates for Kezar Life Sciences’ Q1 2025 earnings at ($2.56) EPS, Q2 2025 earnings at ($2.57) EPS, Q3 2025 earnings at ($2.59) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.33) EPS.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.25.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company reduced their price objective on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 13th.

Kezar Life Sciences Stock Down 4.6 %

Shares of KZR opened at $7.07 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. Kezar Life Sciences has a fifty-two week low of $5.20 and a fifty-two week high of $11.35. The firm has a 50 day moving average price of $7.58 and a 200-day moving average price of $6.77.

Institutional Trading of Kezar Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of Kezar Life Sciences by 15.0% during the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after buying an additional 81,678 shares during the period. XTX Topco Ltd increased its stake in shares of Kezar Life Sciences by 256.1% during the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after buying an additional 37,504 shares during the period. Ikarian Capital LLC increased its stake in shares of Kezar Life Sciences by 23.0% during the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after buying an additional 200,000 shares during the period. Stonepine Capital Management LLC increased its stake in shares of Kezar Life Sciences by 42.0% during the third quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after buying an additional 440,853 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Kezar Life Sciences during the second quarter valued at $63,000. Hedge funds and other institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.